Anoopa Koshy, MD
Endocrinology, Diabetes & Metabolism · Chicago, ILNPI 1003010943
Payments from drug & device makers
Across 70 payments — averaging $31.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$1K
- Amgen$549
- Pfizer$175
- Medtronic$80
- Johnson & Johnson$28
- Cardiovascular Systems Inc.$27
What the payments were for
- Food & beverage$2,195100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 38 | $1,336 |
| Amgen | 22 | $549 |
| Pfizer | 7 | $175 |
| Medtronic | 1 | $80 |
| Johnson & Johnson | 1 | $28 |
| Cardiovascular Systems Inc. | 1 | $27 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DRAGONFLY OPSTAR$176
- SUPERA$173
- PRESSUREWIRE$150
How this compares
$2,195 in reported general payments places this provider in the 65th percentile of 347 endocrinology, diabetes & metabolism providers in Illinois.
See all endocrinology, diabetes & metabolism providers in Illinois →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 135 | $178,599 |
| JardianceEmpagliflozin | 114 | $159,492 |
| TrulicityDulaglutide | 106 | $135,181 |
| JanuviaSitagliptin Phosphate | 53 | $73,723 |
| Humalog Kwikpen U-100Insulin Lispro | 95 | $33,607 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 199 | $31,431 |
| MounjaroTirzepatide | 21 | $29,475 |
| TradjentaLinagliptin | 19 | $28,006 |
| Tresiba Flextouch U-200Insulin Degludec | 18 | $26,417 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 28 | $24,195 |
| Tresiba Flextouch U-100Insulin Degludec | 32 | $21,606 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 132 | $17,908 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 32 | $17,037 |
| RybelsusSemaglutide | 12 | $16,570 |
| Humalog Kwikpen U-200Insulin Lispro | 18 | $15,845 |
Paid to pharmacies, not to this prescriber.
Other endocrinology, diabetes & metabolism in Chicago
- Leon FogelfeldChicago$1.5M
- Grazia AleppoChicago$1.4M
- Wahid KassarChicago$884K
- Wenyu HuangChicago$639K
- Silvana PannainChicago$575K
- Tamara VokesChicago$448K
- George BakrisChicago$429K
- William LoweChicago$372K
- Rajesh JainChicago$285K
- Louis PhilipsonChicago$236K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.